PRMT5 is overexpressed in hepatocellular carcinoma (HCC), and associated with aggressive clinicopathological parameters, such as poor differentiation, higher incidence of hepatic vein invasion, larger tumor size, higher AFP levels and worse prognosis (Shimizu et al., 2017; Jeon et al., 2018). This evidence concerns the gene PRMT5 and hepatocellular carcinoma.